News Releases

December 2, 2019 at 8:02 AM EST

Summary Toggle CryoLife Receives CE Mark for E-nya Thoracic Stent Graft

Product Launch Anticipated in the First Quarter 2020 ATLANTA , Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally
December 2, 2019 at 8:00 AM EST

Summary Toggle CryoLife Receives CE Mark for E-nside Thoraco-abdominal Stent Graft

First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA , Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside
October 30, 2019 at 4:05 PM EDT

Summary Toggle CryoLife Reports Third Quarter 2019 Financial Results

ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ®
October 16, 2019 at 4:35 PM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2019 Third Quarter Financial Results

ATLANTA , Oct. 16, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 third quarter financial results will be released on Wednesday, October 30, 2019 after the market closes.
September 18, 2019 at 8:34 AM EDT

Summary Toggle CryoLife to Participate in the Deutsche Bank 27th Annual Leveraged Finance Conference

ATLANTA , Sept. 18, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat with analysts and investors at the upcoming Deutsche Bank 27 th Annual Leveraged Finance
September 11, 2019 at 4:03 PM EDT

Summary Toggle CryoLife Enters Into Distribution Agreement with Endospan

Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET ATLANTA , Sept. 11, 2019 /PRNewswire/ -- CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery
August 29, 2019 at 8:34 AM EDT

Summary Toggle CryoLife to Participate in Upcoming Investor Conferences

ATLANTA , Aug. 29, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences. CryoLife's management will be presenting at the Morgan Stanley 17th Annual
July 30, 2019 at 4:05 PM EDT

Summary Toggle CryoLife Reports Second Quarter 2019 Financial Results

ATLANTA , July 30, 2019 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Total revenues were $71.1 million in the second quarter of 2019, reflecting year over year growth of 4% and a 7% increase on a non-GAAP constant currency basis, both compared to the second quarter of 2018
July 25, 2019 at 8:34 AM EDT

Summary Toggle CryoLife to Present at Canaccord Genuity 39th Annual Growth Conference

ATLANTA , July 25, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Canaccord Genuity 39 th Annual Growth Conference on Thursday, August 8, 2019 at the InterContinental Boston Hotel .
July 17, 2019 at 8:34 AM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2019 Second Quarter Financial Results

ATLANTA , July 17, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 second quarter financial results will be released on Tuesday, July 30, 2019 after the market closes. On that day, the Company will